

































represent	 an	 enriched	 subset	 of	 the	 non-coding	 genome	 in	 which	 to	 search	 for	 driver	
mutations.	 We	 identify	 regulatory	 regions	 whose	 mutation	 significantly	 alters	 gene	
expression,	 including	 copy	 number	 variation	 at	 cis-regulatory	 elements	 targeting	 CD69,	
IGLL5	 and	MMP14,	 and	 single-nucleotide	 variants	 in	 a	 cis-regulatory	 element	 for	 TPRG1.	
Additionally,	we	 demonstrate	 the	 commonality	 of	 pathways	 targeted	 by	 coding	 and	 non-
coding	 mutations,	 exemplified	 by	 MMP14,	 which	 regulates	 Notch	 signaling,	 a	 pathway	
important	 in	 lymphomagenesis,	 and	whose	 expression	 is	 associated	with	 patient	 survival.	
This	study	provides	an	enhanced	understanding	of	lymphomagenesis	and	demonstrates	the	













B-cell	 lymphoma	 comprise	 a	 heterogeneous	 group	 of	 cancers,	 with	 diverse	 etiologies,	
clinical	behaviors	and	outcomes1.	The	different	B-cell	lymphoma	resemble	B	cells	at	specific	
stages	 of	 differentiation1,	 with	 diffuse	 large	 B-cell	 lymphoma	 (DLBCL)	 and	 follicular	
lymphoma	(FL),	accounting	for	around	43%	and	17%	of	cases	respectively2.		
	
The	 identification	 of	 driver	 mutations	 is	 fundamental	 to	 understanding	 oncogenesis	 and	
response	 to	 therapy.	 Although	 studies	 have	 identified	 genes	 and	 pathways	 frequently	
mutated	 in	B-cell	 lymphoma3-8,	many	tumors	have	no	detectable	driver	mutations	and	we	




to	 coding	 regions3-6.	Gene	 regulation	 is	 highly	 cell-type	 specific,	 and	 the	 interpretation	 of	
mutations	within	non-coding	regions	of	lymphoma	genomes	has	been	in	part	constrained	by	
a	 lack	 of	 information	 on	 relevant	 regulatory	 elements	 and	 their	 target	 genes9,10.	
Furthermore,	although	mutation	recurrence	 is	an	 indicator	of	positive	selection	 in	tumors,	
the	 sheer	 size	 of	 the	 non-coding	 genome	places	 a	 high	 statistical	 burden	on	 an	 ability	 to	
distinguish	passenger	from	driver	mutations.		
	
Cis-regulatory	 elements	 (CREs)	 and	 promoters	 controlling	 gene	 expression	 represent	 a	
highly	 enriched	 subset	 of	 the	 non-coding	 genome	 in	which	 to	 search	 for	 potential	 driver	
mutations11.	 Herein	we	 have	 exploited	 this	 principle	 by	 using	 information	 from	promoter	
		 5	
capture	 Hi-C	 (CHi-C)	 in	 naïve	 B	 cells12	 in	 an	 analysis	 of	 whole-genome	 sequencing	 (WGS)	
data	on	80	DLBCL	and	37	FL	tumors.	By	linking	CRE	mutation	to	gene	expression	(Figure	1),	
we	 identify	 recurrently	 mutated	 non-coding	 regulatory	 regions,	 enhancing	 our	







normal	 samples,	 were	 obtained	 from	 the	 International	 Cancer	 Genome	 Consortium	
(ICGC)5,13.	 Data	 from	 an	 additional	 40	 DLBCL	 tumors	 and	matched	 normal	 samples	 were	
obtained	 from	 The	 Cancer	 Genome	 Characterization	 Initiative	 (CGCI)8.	 The	 ICGC	 data	 has	
been	 aligned,	 processed	 and	 variants	 called	 as	 part	 of	 the	 Pan-Cancer	 Analysis	 of	Whole	
Genomes	 (PCAWG)	 project.	 A	 consensus	 approach	 to	 variant	 calling	 was	 adopted	 by	
PCAWG,	 combining	 the	 results	 of	 multiple	 pipelines	 to	 call	 SNVs,	 indels,	 CNVs	 and	 SVs	
(https://github.com/ICGC-TCGA-PanCancer).	 For	 each	 mutation	 type	 we	 downloaded	 and	
used	variants	called	by	a	respective	pipeline.	To	minimize	technical	differences	between	the	
cohorts,	we	aligned,	processed	and	called	variants	in	the	CGCI	data	using	identical	pipelines,	
as	 described	 in	 Supplementary	 Methods.	 RNA-sequencing	 data	 for	 all	 samples	 were	
obtained	from	the	CGCI	and	 ICGC	and	processed	as	described	 in	Supplementary	Methods.	




Promoter	 regions	 were	 defined	 as	 the	 intervals	 spanning	 400bp	 upstream	 to	 250bp	
downstream	of	transcription	start	sites	from	RefGene14.	CREs	were	defined	using	promoter	











specific	 mutation	 rates17,	 which	 is	 not	 possible	 using	 many	 alternative	 approaches18,19.	
Briefly,	the	mutation	probability	of	each	regulatory	region	in	each	tumor	was	computed	by	
fitting	 a	 logistic	 regression	model	 to	 all	 data,	 taking	 into	 account	 the	 following	 features:	








! region is mutated =  1−  (1−  !!)!!!! 	
where	i	is	the	base	position,	s	is	the	number	of	nucleotides	considered	in	the	region	(i.e.	not	
excluded)	and	pi	is	the	probability	that	a	mutation	occurs	at	base	i.	P-values	were	computed	
for	 each	 promoter	 and	 CRE	 using	 an	 approximation	 of	 the	 Poisson	 binomial	 model	
implemented	 in	 the	 poibin	 R-package17.	 Recurrent	 mutation	 P-values	 follow	 a	 discreet	
		 8	




Significantly	 mutated	 CREs	 were	 examined	 for	 differential	 expression	 of	 target	 genes	
between	mutated	and	non-mutated	tumors.	For	each	CRE,	tumors	were	classified	mutated	
or	 non-mutated	 based	 on	 the	 presence	 of	 SNVs	 or	 indels	 at	 the	 CRE,	 and	 differential	
expression	 assessed	 using	 permutation	 testing22.	 In	 the	 permutation	 testing	 a	 t-test	 was	
performed	using	 the	mutated/non-mutated	 tumor	 labels	 to	generate	a	 single	 t-value	 (the	
observed	 t-value).	The	expression	values	 for	 the	mutated/non-mutated	 tumors	were	 then	
permuted	 10,000	 times	 to	 generate	 10,000	 additional	 t-values	 (the	 permutated	 t-values).	
The	permuted	 t-values	generally	 fit	a	Gaussian	distribution,	against	which	 the	observed	 t-
value	could	be	compared	using	a	two-tailed	test22.	Samples	with	CNVs	at	either	the	CRE	or	
target	 gene	 were	 excluded.	 Additionally,	 samples	 with	 translocation	 or	 inversion	
breakpoints	≤1Mb	from	the	target	gene	were	excluded.	Only	CREs	mutated	in	at	 least	five	
tumors	 were	 tested,	 after	 removal	 of	 tumors	 with	 CNVs	 at	 the	 CRE	 or	 target	 gene,	 or	
proximal	 translocation	 or	 inversion	 breakpoints.	 CREs	 interacting	 with	 multiple	 gene	
promoters	were	tested	multiple	times.	Only	CREs	interacting	with	the	promoters	of	protein-










and	log2-transformed	gene	expression	e	by	fitting	a	linear	regression	model:	! =  !! +  !!!.	
A	t-statistic	was	computed	using	the	estimated	!!	coefficient	and	standard	error,	and	a	P-
value	 was	 computed	 from	 this	 t-statistic	 under	 the	 null	 hypothesis	 of	 no	 association	
between	 copy	 number	 change	 and	 gene	 expression	 (!! = 0).	 Only	 regulatory	 regions	
mutated	 in	 at	 least	 five	 tumors	were	 tested,	 after	 exclusion	 of	 tumors	with	 CNVs	 at	 the	
target	 gene	 or	 proximal	 translocation	 and	 inversion	 breakpoints.	 Copy	 number	 changes	
were	 calculated	 relative	 to	 the	 ploidy	 of	 the	 tumor,	 as	 determined	 by	 ascatNgs23.	 For	
simplicity,	 all	 losses	 and	 gains	 were	 considered	 equally	 when	 calculating	 correlation	
coefficients	 (i.e.	each	 tumor	 is	defined	as	having	either	a	 loss,	no	change,	or	gain	 in	 copy	
number).	 In	 addition	 to	 conducting	 individual	 analyses	 of	 DLBCL	 and	 FL	 tumors,	 we	
completed	 a	 meta-analysis	 of	 the	 two	 tumor	 types	 under	 a	 fixed	 effects	 model.	 The	






Reddy	et	 al.6,	which	were	downloaded	 from	GEO.	Patients	were	 censored	based	on	 their	





the	 Wald	 test	 was	 used	 to	 determine	 statistical	 significance.	 The	 proportional	 hazards	
assumption	in	the	Cox	models	was	assessed	using	scaled	Schoenfeld	residuals	implemented	
in	 the	 “cox.zph”	 function	 from	 the	 survival	 R-package.	Meta-analyses	 of	 the	 independent	
patient	cohorts	were	performed	under	a	fixed-effects	model.	We	also	stratified	cancers	by	
the	expression	of	the	gene,	defining	tumors	as	having	high	or	low	expression	of	a	gene	if	the	







Coordination	 Center	 (DCC)	 Data	 Portal	 (project	 codes	 MALY-DE	 and	 CLLE-ES).	 CGCI	 data	
were	downloaded	from	dbGaP	(phs000532.v7).	Naïve	B-cell	CHi-C	data	were	obtained	from	
Javierre	et	al12.	Histone	ChIP-seq	data	were	downloaded	from	BLUEPRINT	(sample	C005Q).	









After	 quality	 control	 and	 filtering	 of	WGS	 data,	we	 identified	 1,169,005	 single	 nucleotide	
variants	 (SNVs)	 in	 the	 DLBCL	 tumors	 (5.07	 mutations	 per	 megabase	 [Mb]),	 and	 255,889	
SNVs	 in	 FL	 tumors	 (2.40	mutations	 per	Mb;	Table	 S1).	 Recurrently	mutated	 regions	were	
identified	as	those	containing	a	greater	number	of	mutations	than	that	expected	given	the	




in	DLBCL	and	FL	tumors	respectively	 (Q<0.1,	Table	S2).	These	genes	 include	BLK,	 IRF8	and	
SPIB,	 which	 are	 implicated	 in	 lymphoma	 development	 and	 growth26-28,	 but	 for	 which	
recurrent	promoter	mutations	have	not	previously	been	reported9.		
	
Using	 promoter	 CHi-C	 in	 naïve	B	 cells12	we	defined	69,872	 genomic	 fragments	 containing	
putative	CREs	(median	size	2.1Kb),	 involved	in	142,791	unique	significant	 interactions	with	
promoters	 (median	 linear	 distance	 292Kb)	 and	 constituting	 7%	 of	 the	 genome.	 These	
promoter-interacting	 fragments	have	previously	been	 shown	 to	be	enriched	 for	ATAC-seq	
accessibility	 and	 regulatory	 histone	 marks12.	 We	 identified	 78	 recurrently	 mutated	 CREs	






and	 eight	 recurrently	 mutated	 CRE	 fragments	 in	 DLBCL	 and	 FL	 respectively,	 and	 whose	
expression	 is	disrupted	by	non-coding	mutations	 in	chronic	 lymphoblastic	 leukemia	(CLL)13	






We	 used	 Palimpsest	 to	 characterise	 the	 processes	 most	 likely	 to	 be	 responsible	 for	 the	
recurrent	 mutation	 of	 promoters	 and	 CREs	 (Tables	 S4,	 S5	 and	 S6;	 Supplementary	
Methods)30-32.	 In	 DLBCL,	 promoters	 and	 CREs	 of	 genes	 including	 BCL6	were	 enriched	 for	
mutations	attributed	to	signatures	SBS84	or	SBS85	(P	<	0.05;	Table	S4),	which	are	associated	
with	 the	 activity	 of	 activation-induced	 deaminase	 (AID)32,	 supporting	 previous	
observations33.	Furthermore,	the	promoters	and	CREs	of	multiple	genes,	including	SGK1	and	
ST6GAL1	in	DLBCL,	were	enriched	for	mutations	attributed	to	signature	SBS3	(Table	S4	and	




levels	 of	 target	 genes	 of	 recurrently	 mutated	 CREs	 between	 mutated	 and	 non-mutated	
tumors,	 using	 RNAseq	 data	 from	 each	 tumor.	 Tumors	 with	 copy	 number	 changes	
overlapping	 either	 the	 CRE	 or	 target	 gene,	 and	 tumors	 with	 translocation	 or	 inversion	
breakpoints	≤1Mb	from	the	target	gene	were	excluded	from	this	analysis.	Mutation	of	a	CRE	
		 13	
interacting	with	 the	TPRG1	promoter,	occurring	 in	nine	 tumors	 (Figure	2),	was	associated	
with	 increased	 TPRG1	 expression	 in	 DLBCL	 (Q=0.09,	 Figure	 3,	 Table	 S7).	 This	 CRE	 is	
annotated	 by	 epigenetic	 marks	 indicative	 of	 active	 enhancers	 (Figure	 3,	 Figure	 S1,	
Supplementary	Methods)	and	located	at	a	regulatory	region	previously	identified	in	DLBCL	






has	 previously	 been	 reported	 in	 B-cell	 lymphoma,	 it	 was	 not	 previously	 associated	 with	
disrupted	 TPRG1	 expression9.	 This	 TPRG1	 CRE	 is	 enriched	 for	 mutations	 attributed	 to	
signatures	SBS84	(P=0.002)	and	SBS85	(P=0.030)	(Table	S5),	consistent	with	it	being	a	target	




To	 identify	 CREs	 subject	 to	 somatic	 copy	 number	 variation	 (CNV),	 we	 identified	 CNVs	 in	
tumors	using	WGS	data	(Figure	2).	CNV-positive	CREs	were	assessed	for	a	correlation	with	
the	expression	of	target	genes,	excluding	cases	where	the	gene	was	encompassed	by	a	CNV,	






The	 CD69	 promoter	 interacts	 with	 a	 CRE	 annotated	 by	 multiple	 epigenetic	 marks,	
overlapping	a	DLBCL	BRD4-bound	regulatory	region	(Figure	4A,	Figure	S2)35.	This	CRE	region	
is	 deleted	 in	 five	 DLBCL	 tumors,	 which	 were	 associated	 with	 higher	 CD69	 expression	
(Q=0.06,	 Figure	 4B,	 Table	 S8),	 suggesting	 this	 element	 acts	 as	 a	 repressor	 of	 CD69	
expression.	 CD69	 plays	 a	 role	 in	 B-cell	 development	 in	 mice39	 and	 enhanced	 antitumor	
immunity	has	been	observed	 in	mice	deficient	 in	CD6940.	Higher	CD69	protein	expression	
has	 previously	 been	 associated	 with	 shorter	 survival	 in	 B-cell	 lymphoma	 patients41,42,	
although	we	 did	 not	 replicate	 this	 association	with	 RNA	 expression	 in	 three	 independent	
series	 totaling	 1,670	 DLBCL	 cases	 (Table	 S9).	 Whilst	 deletion	 of	 the	 CD69	 CRE	 was	
accompanied	by	ETV6	exon	deletions	 in	 three	of	 the	 five	 tumors,	altered	ETV6	expression	
was	not	observed	in	these	samples	(Figure	4C).	
	
The	 T-cell	 receptor	 alpha	 (TRA)	 locus,	which	 undergoes	 V(D)J	 recombination	 during	 T-cell	
development43,	is	the	subject	of	copy	number	losses	and	gains	in	both	DLBCL	and	FL	tumors	
(Table	 S8).	 This	 region	 is	 annotated	with	multiple	 histone	marks	 and	 contains	 two	DLBCL	
BRD4-bound	regulatory	regions35	(Figure	5A,	Figure	S3).	 	 In	DLBCL,	eight	CRE	fragments	at	
the	TRA	locus	were	deleted	in	20	and	amplified	in	11	tumors.	These	CRE	fragments	contact	
the	promoters	of	 16	 genes,	with	 copy	number	 changes	 associated	with	 the	expression	of	
ABHD4,	LRP10,	MMP14,	PRMT5	and	SLC7A7	(Q<0.1,	Figure	5B-C,	Table	S8).	In	FL,	these	CRE	
fragments	 were	 deleted	 in	 17	 tumors	 and	 amplified	 in	 one,	 with	 copy	 number	 changes	
associated	 with	 the	 expression	 of	 only	 ACIN1	 (Q=0.04,	 Table	 S8).	 In	 the	 DLBCL	 tumors,	






CRE	 copy	 number	 was	 associated	 with	 increased	 PRMT5	 expression	 in	 DLBCL	 tumors	




Although	 copy	number	 changes	 at	 the	 TRA	 locus	have	previously	 been	observed	 in	B-cell	
malignancies46-48,	 it	 is	disputed	whether	 these	variants	are	pathogenic	 lesions	occurring	 in	









in	 all	 11	 DLBCL	 samples	 and	 in	 the	 one	 FL	 sample	with	 TRA	 locus	 amplifications,	 normal	






effects	 model	 (Table	 S10).	 In	 this	 meta-analysis,	 CNV-positive	 CREs	 interacting	 with	 the	
promoters	 of	MMP14,	 PRMT5	 and	 SLC7A7	were	 associated	with	 the	 expression	 of	 these	
genes	 (Q<0.1),	 suggesting	 a	 common	 effect	 of	 these	 CNVs	 on	 target	 gene	 expression	 in	
these	B-cell	malignancies.		
	
Meta-analysis	 of	 the	 DLBCL	 and	 FL	 tumors	 also	 identified	 two	 CREs	 interacting	 with	 the	





IGLL1,	 a	 gene	which	plays	 a	 critical	 role	 in	B-cell	 development52.	 	 Furthermore,	 IGLL5	has	
been	shown	to	function	as	a	tumor	suppressor	in	a	CRISPR-based	screen	of	DLBCL	cell	lines6,	
a	 finding	 in	 keeping	 with	 reduced	 IGLL5	 expression	 being	 associated	 with	 CRE	 deletion.	
Although	 focal	 deletion	 of	 regions	 encompassing	 the	 IGLL5	 CRE	 occur	 in	 other	 B-cell	
malignancies,	 including	 childhood	 acute	 lymphoblastic	 leukemia	 (ALL)53	 and	 CLL54,	 their	













We	 examined	 whether	 tumors	 harboring	 CNV-positive	 CREs	 associated	 with	 target	 gene	
expression	 were	 enriched	 for	 DLBCL	 tumors	 of	 either	 the	 activated	 B-cell-like	 (ABC)	 or	
germinal	 center	B-cell-like	 (GCB)	 cell-of-origin	 (COO)	 subtypes	 (Table	 S11,	 Supplementary	




To	 better	 inform	 the	 interplay	 between	 non-coding	 driver	mutations	 with	 other	 driver	
mechanisms,	 we	 identified	 pathways	 targeted	 by	 coding	 and	 non-coding	 mutations,	
combining	 genes	 identified	 in	 this	 analysis	 and	 genes	 with	 recurrent	 coding	mutations	
from	 an	 analysis	 of	 1,001	DLBCL	whole	 exomes6	 (Table	 S12,	Supplementary	Methods).	
One	pathway	identified	is	Notch	signaling	(Q=2.1×10-4),	which	contains	genes	affected	by	
coding	mutations,	such	as	CREBBP,	and	genes	affected	by	non-coding	mutations,	such	as	







This	 analysis	 has	 identified	 putative	 non-coding	 driver	mutations	 in	 B-cell	 lymphoma	 and	









It	 has	 previously	 been	 demonstrated	 that	 disruption	 of	 the	 Notch-signaling	 pathway,	




V(D)J	 recombinase	 recognizes	 recombination	 sequence	 signals	 (RSSs),	 which	 consist	 of		
conserved	 heptamer	 and	 nonamer	 elements	 separated	 by	 a	 spacer58.	 We	 identified	 RSS	
sites	adjacent	to	the	boundaries	of	11/49	TRA	locus	CNVs,	10/25	 IGLL5	CRE	CNVs,	and	0/5	
CD69	CRE	CNVs	(Table	S13).	Calling	RSS	sites	is	inherently	difficult,	due	to	some	sites	being	
less	 conserved	 nor	 adjacent	 to	 identified	 breakpoints59.	 Therefore,	 whilst	 this	 analysis	




Here	 we	 utilize	 naïve	 B-cell	 CHi-C	 data	 to	 characterize	 CREs	 and	 map	 them	 to	 their	
respective	 target	 genes.	 DLBCL	 and	 FL	 tumors	 develop	 from	 B	 cells	 at	 various	 stages	 of	
differentiation1,	 and	 naïve	 B-cell	 CHi-C	 data	 may	 therefore	 not	 fully	 recapitulate	 the	
regulatory	 interactions	 active	 in	 each	 tumors’	 COO.	 Nevertheless,	 many	 interactions	
involving	 mutated	 CREs	 associated	 with	 differential	 target	 gene	 expression	 are	 also	
observed	in	total	B-cell	CHi-C	data	(Table	S14)12,	suggesting	that	these	interactions	may	not	







It	 is	 also	 possible	 that	 some	 CREs	 contain	 a	 mixture	 of	 mutations	 that	 do	 and	 do	 not	
affect	gene	expression,	thereby	reducing	study	power.	Secondly,	we	do	not	consider	the	
clonality	 of	mutations	 in	 the	 differential	 expression	 analysis.	 Thirdly,	we	 did	 not	 assess	





cell	 lymphomagenesis,	 and	 provide	 further	 insight	 into	 the	 genetic	 complexity	 of	 B-cell	
lymphoma.	 Furthermore	 this	 study	 illustrates	 the	 advantages	 of	 using	 information	 from	
		 20	
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performed	 bioinformatic	 analyses.	 A.J.C.	 performed	 statistical	 analyses.	 A.J.C.	 and	 R.S.H.	












































































































































































Figure	 2:	 Overview	 of	 CRE	mutations,	 amplifications	 and	 losses	 associated	with	 altered	
target	 gene	 expression	 in	 DLBCL	 and	 FL.	 Top	 panel	 shows	 the	 genome-wide	 mutation	
burden	for	each	tumor.	Second	panel	shows	the	occurrence	of	SNVs	in	the	TPRG1	CRE.	Third	
panel	 shows	 the	 occurrence	 of	 amplifications	 and	 losses	 at	 CREs	 associated	with	 altered	




expression	 in	 DLBCL.	 (A)	 SNVs	 at	 a	 CRE	 interacting	with	 the	TPRG1	promoter.	 Top	 panel	
shows	 position	 of	 SNVs	 at	 the	 CRE.	 Second	 panel	 shows	 chromatin	 looping	 interactions	
between	 the	TPRG1	promoter	 and	CREs,	with	 the	 interaction	 between	 the	 promoter	 and	
the	SNV-disrupted	CRE	colored	yellow.	Third	panel	details	ChIP-seq	histone	mark	signals	in	
naïve	B-cells.	Bottom	panels	show	positions	of	BRD4-bound	enhancers	 in	DLBCL35.	 (B)	CRE	
mutation	 status	 and	 gene	 expression.	 Whilst	 the	 TPRG1	 CRE	 is	 mutated	 in	 nine	 DLBCL	






Figure	 4:	 Copy	 number	 variation	 at	 cis-regulatory	 element	 is	 associated	 with	 CD69	
expression	in	DLBCL.	(A)	Loss	of	a	CRE	interacting	with	the	CD69	promoter.	Top	panel	shows	
position	of	CNVs	at	CRE,	all	of	which	are	copy	number	losses.	Second	panel	shows	chromatin	
looping	 interactions	between	 the	CD69	promoter	and	CREs,	with	 the	 interaction	between	
the	 promoter	 and	 the	 CNV-disrupted	 CRE	 colored	 yellow.	 Third	 panel	 details	 ChIP-seq	
histone	 mark	 signals	 in	 naïve	 B-cells.	 Bottom	 panel	 shows	 positions	 of	 BRD4-bound	
enhancers	in	DLBCL35.	(B)	CNV	status	at	CRE	and	CD69	expression	in	DLBCL	tumors.	(C)	CNV	







MMP14	and	PRMT5	promoters.	 Top	panel	 shows	position	 of	 CNVs	 at	 the	 CRE;	with	 copy	
number	gains	and	losses	represented	by	solid	and	dashed	lines	respectively.	Second	panel	
shows	 chromatin	 looping	 interactions	 between	 the	MMP14	 and	 PRMT5	 promoters	 and	
CREs,	with	the	interaction	between	the	promoters	and	the	considered	CRE	colored	yellow.	
Third	 panel	 details	 ChIP-seq	 histone	 mark	 signals	 in	 naïve	 B-cells.	 Bottom	 panels	 show	
positions	 of	 BRD4-bound	 enhancers	 in	 DLBCL4.	 CNV	 status	 at	 CRE	 and	 expression	 of	 (B)	
MMP14	and	 (C)	PRMT5	 in	 DLBCL	 tumors.	Whilst	 the	 CREs	 are	 lost	 in	 20	 tumors,	 only	 19	
		 31	
tumors	are	considered	in	the	differential	expression	analysis,	as	one	tumor	also	has	a	CNV	at	




Figure	 6:	 Copy	 number	 variation	 at	 cis-regulatory	 element	 is	 associated	 with	 IGLL5	
expression	in	B-cell	malignancies.	(A)	The	loss	of	a	CRE	interacting	with	the	IGLL5	promoter.	
Top	panel	shows	position	of	CNVs	at	the	CRE,	all	of	which	are	losses,	and	the	position	of	the	
VJ	 junction.	 Second	 panel	 shows	 chromatin	 looping	 interactions	 between	 the	 IGLL5	
promoter	 and	 CREs,	 with	 the	 interaction	 between	 the	 promoter	 and	 the	 considered	 CRE	
colored	 yellow.	 Third	 panel	 details	 ChIP-seq	histone	mark	 signals	 in	 naïve	B-cells.	 Bottom	
panels	shows	positions	of	BRD4-bound	enhancers	 in	DLBCL35.	CNV	status	at	CRE	and	gene	
expression	 in	 (B)	DLBCL	 and	 (C)	 FL	 tumors.	 (D)	CNV	 status	 at	CRE	and	gene	expression	 in	


























CGCI and ICGC data
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CD69 in DLBCL tumors
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MMP14 in DLBCL tumors
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as	 tumor	 and	matched-normal	 BAM	 files	 aligned	 to	 GRCh37.	WGS	 data	 from	 the	
CGCI	 samples	 were	 downloaded	 from	 dbGaP	 as	 tumor	 and	 matched-normal	
unaligned	FASTQ	files.	We	aligned	CGCI	sample	reads	to	the	same	version	of	GRCh37	
employed	 in	 the	PCAWG	project,	using	BWA	MEM1.	Duplicate	 reads	were	marked,	




For	 the	 ICGC	 samples,	 sets	 of	 SNVs,	 called	 using	 MuTect3	 with	 data	 from	 dbSNP	
v1324	 and	 COSMIC	 noncoding	 variants	 v545	 used	 for	 additional	 support,	 were	
downloaded	 from	 the	 ICGC	 DCC	 Data	 Portal.	 For	 the	 CGCI	 samples,	 we	 called	
mutations	across	the	whole	genome	using	MuTect	and	data	from	the	same	versions	
of	 dbSNP	 and	 COSMIC.	 For	 both	 the	 ICGC	 and	 CGCI	 samples	 we	 used	 FoxoG	 to	
remove	any	mutations	that	may	have	been	caused	by	oxidative	DNA	damage	during	




positives,	 the	 Duke	 excluded	 and	 HiSeqDepth	 top	 5%	 regions	 defined	 by	 UCSC	
Genome	 Browser	 were	 omitted	 from	 the	 analysis.	 Furthermore,	 we	 excluded	










For	 the	 ICGC	 samples,	 somatic	 CNVs	 called	 using	 ascatNgs8,	 and	 translocation	 and	






ICGC	 DCC	 Data	 Portal.	 As	 part	 of	 the	 PCAWG	 project,	 reads	 in	 these	 files	 were	
aligned	to	GRCh37	using	TopHat210	and	GENCODE	v19	annotated	mRNA	transcripts.	
We	 downloaded	 CGCI	 tumor	 sample	 RNA-seq	 data	 as	 unaligned	 FASTQ	 files	 from	















promoter-CRE	 interactions.	 To	 identify	 CREs	 not	 mapping	 to	 unique	 locations	 in	
hg38,	hg19	was	split	into	windows	of	100bp	prior	to	alignment	to	hg38	using	BWA.	
Bases	where	the	majority	of	reads	containing	 it	could	be	mapped	elsewhere	 in	the	
genome	 with	 at	 most	 one	 mismatch	 or	 gap	 were	 defined	 as	 poorly	 mapped	










(AID)	 tend	 to	 cluster	 in	 the	 genome18,	 and	 we	 therefore	 classified	 mutations	 as	
clustered	 or	 non-clustered	 and	 attributed	 signatures	 to	 these	 mutations	
separately15.	Mutations	were	 classified	as	 clustered	 if	 the	minimum	distance	 to	all	
other	 mutations	 on	 the	 same	 chromosome	 in	 the	 same	 tumour	 was	 less	 than	
1,000bp18.	 The	numbers	 of	 clustered	 and	non-clustered	mutations	 associated	with	
each	 signature	 in	 each	 tumour	 was	 then	 summed	 to	 calculate	 the	 overall	
contribution	of	each	signature	to	each	tumour.	As	per	Letouzé	et	al.16,	we	computed	
the	 probability	 that	 each	 somatic	 mutation	 occurs	 as	 a	 result	 of	 the	 process	
underlying	 each	 mutational	 signature,	 considering	 the	 substitution	 type	 and	 the	
overall	 contribution	 of	 each	 signature	 to	 each	 tumour.	 To	 assess	 whether	 each	
recurrently	mutated	promoter	and	CRE	was	enriched	with	mutations	attributed	 to	
each	 signature,	 we	 compared	 the	 probability	 distribution	 of	 mutations	 in	 the	
regulatory	element	to	the	probability	distribution	of	all	other	mutations	observed	in	
tumours	in	which	the	regulatory	element	was	mutated,	using	a	one-sided	Wilcoxon	














For	 those	 CREs	 affected	 by	 mutations	 associated	 with	 differential	 target	 gene	





The	 tendency	 of	 coding	 and	 non-coding	 mutations	 affecting	 genes	 to	 occur	 in	
different	 tumors	 was	 assessed	 using	 a	 two-tailed	 Fisher’s	 exact	 test.	 Pathways	





ChIP-seq	data	 from	naïve	B	 cells	 (NC14_42),	 CD38-negative	naïve	B	 cells	 (S004KB),	
germinal	 center	 B	 cells	 (T14_10),	 unswitched	 memory	 B	 cells	 (pool_9)	 and	 class-
switched	memory	B	cells	 (csMBC_pool_2)	 for	H3K4me1,	H3K27me3,	H3K9me3	and	
H3K36me3	 were	 downloaded	 from	 BLUEPRINT.	 Co-ordinates	 were	 mapped	 from	
GRCh38	 to	GRCh37	using	 liftOver.	 BRD4-loaded	 enhancers,	 defined	using	 ChIP-seq	
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Figure S1: SNVs at a CRE interacting with the TPRG1 promoter. Top panel shows position of the CRE. Second panel shows chromatin looping 
interactions between the TPRG1 promoter and CREs, with the interaction between the promoter and the SNV-disrupted CRE colored yellow. 
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Figure S2. Loss of a CRE interacting with the CD69 promoter. Top panel shows position of CNVs at the CRE, all of which are copy number 
losses. Second panel shows chromatin looping interactions between the CD69 promoter and CREs, with the interaction between the promoter 
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Figure S3. Gain and loss of a CRE interacting with the MMP14 and PRMT5 promoters. Top panel shows position of CNVs at the CRE; with 
copy number gains and losses represented by solid and dashed lines respectively. Second panel shows chromatin looping interactions between 
the MMP14 and PRMT5 promoters and CREs, with the interaction between the promoters and the considered CRE colored yellow. Lower 
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CNVs
Figure S4. Kaplan-Meier survival analysis of (A) MMP14 and (B) PRMT5 expression (the two genes with expression significantly associated 
with survival in the Cox proportional hazards model analysis) in data sets from Barrans et al. (n=115), Lenz et al. (n=276) and Reddy et al. 
(n=404). Distribution differences assessed using the log-rank test. 
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Figure S5. Loss of a CRE interacting with the IGLL5 promoter. Top panel shows position of CNVs at the CRE, all of which are losses, and the 
position of the VJ junction. Second panel shows chromatin looping interactions between the IGLL5 promoter and CREs, with the interaction 
between the promoter and the considered CRE colored yellow. Lower panels detail ChIP-seq histone mark signals in B cells at different 
differentiation stages.
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